Navigation Links
Januvia Lawsuits Move Forward, With Scheduling of Next Status Conference in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
Date:11/9/2013

New York, New York (PRWEB) November 09, 2013

The federal multidistrict litigation established for Januvia lawsuits (http://www.januvialawsuithelp.com) will hold its next Status Conference on November 21, 2013, Bernstein Liebhard LLP reports. According to court filings, at least 150 lawsuits involving Januvia and other Type 2 diabetes drugs in the incretin mimetics class are now pending in the federal proceeding, which is underway in U.S. District Court, Southern District of California. All of the claims filed in the litigation allege that doctors and patients were not provided with adequate warnings regarding a potential association between medications like Januvia and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm is pleased with the progress of this litigation thus far, as we continue to hear from Januvia patients who are concerned that this drug may have caused them to develop pancreatic cancer, as well as pancreatitis and thyroid cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Januvia lawsuit evaluations to individuals who were allegedly harmed by this medication.

Januvia and Pancreatic Cancer
Januvia and other incretin mimetic drugs work by copying the action of incretin hormones in the digestive tract to stimulate the production of insulin by the pancreas. In 2009, a caution regarding a link between Januvia and pancreatitis – a risk factor for pancreatic cancer - was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 instances where Januvia patients had developed acute pancreatitis.* Since then, additional studies have raised concerns that drugs like Januvia may have harmful affects on the pancreas, including one that was published in Gastroenterology in 2011 which found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer. The study also noted that two cases of thyroid cancer were also reported in the patients who took Januvia.**

This past March, the FDA announced that it was investigating Januvia and other incretin mimetics after results from an unpublished study linked the drugs to pre-cancerous changes in the cells of the pancreas. While the agency has not yet been able to confirm a conclusive link between the use of medications like Januvia and pancreatic cancer, it has said its review is ongoing as pancreatitis and pancreatic cancer data are being collected. Just a month after the FDA announced its review, the Institute for Safe Medicine Practices (ISMP) published an analysis of the FDA adverse event database that revealed 177 cases of pancreatitis in patients who took Januvia, 18 instances of pancreatic cancer, and one thyroid cancer report in individuals who took the drug.***

Alleged victims of Januvia and pancreatic cancer, thyroid cancer or pancreatitis could be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about possible Januvia side effects by visiting Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm, FDA, September 2009
**gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract; Gastroenterology, February 21, 2011
***ismp.org/QuarterWatch/pdfs/2012Q3.pdf, ISMP, April 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuithelp.com

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11318046.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Updates with Latest Case Numbers Since Januvia Lawsuits Sent to MDL Court
2. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
3. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
4. Januvia Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Order Transferring Federal Claims Over Januvia and Pancreatic Cancer to California Federal Court
5. Januvia Lawsuits Being Investigated By Bernstein Liebhard LLP on Behalf of Januvia Patients Who Were Diagnosed with Pancreatic Cancer, Pancreatitis and Thyroid Cancer
6. Januvia Pancreatic Cancer Lawsuit: Bernstein Liebhard LLP Comments on Growing Litigation Surrounding Januvia
7. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
8. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
9. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
10. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
11. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, ... demanding job, and no time to decompress, Rabinowitz found herself drawn to a casual ... for its impact on her life, implementing a 20-minute-per-day meditation practice with her team. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
(Date:2/12/2016)... Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, ... Fisher House at the VA Southern Nevada Healthcare System. This will be the ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... , ... Donor Network West, the organ procurement organization that heals lives through ... Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific organ ... more certain time frame for donor families for the recovery of organs. , ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology: